Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. filed an 8-K reporting that on March 16, 2026 it entered a Note Purchase Agreement with Atlas Sciences, LLC and issued an unsecured promissory note with an original principal of $18,360,000 (issued at a $1,360,000 discount for a $17,000,000 purchase price). The Company must use the $17.0M proceeds solely to partially repay $17.0M of its existing convertible promissory note with Avondale Capital, LLC (the Avondale Note). After that payment, $10,806,991 remains outstanding under the Avondale Note. The Company and Avondale also executed an amendment extending the Avondale Note’s maturity to December 31, 2026.

Key Details

• Note issued to Atlas Sciences on March 16, 2026: original principal $18,360,000; purchase price $17,000,000 (original issue discount $1,360,000).
• Use of proceeds: exclusively to repay $17,000,000 of the Avondale convertible note; remaining Avondale obligation $10,806,991.
• Note economics and rights: interest = prime rate + 3% (floor 9.5%); maturity = 15 months after closing; Investor can redeem up to $3,000,000 per quarter beginning six months after closing; all cash payments (prepayments, redemptions, maturity) carry a 7.5% exit fee.
• Covenants and defaults: customary representations, covenants (e.g., timely SEC filings, maintain Nasdaq listing, restrictions on encumbering assets and certain issuances without investor consent) and customary default/cure provisions.
• The Company filed supplemental risk factors (Exhibit 99.1) related to the transaction.

Why It Matters
This transaction creates a new unsecured debt obligation (note principal $18.36M, $17.0M funded) and immediately reduces one existing convertible debt balance by $17.0M while extending the remaining Avondale maturity to year-end 2026. The note carries relatively high effective financing costs (interest floor of 9.5% plus a 7.5% exit fee) and includes redemption rights and covenants that could affect the Company’s financing flexibility. Retail investors should review the supplemental risk factors and the full agreements for details on repayment terms, potential cash obligations, and any restrictions that may affect future capital raising.